Drugs / 68Ga-MY
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07589101 | Jun 2026 → Jun 2027 expected | breast cancer, lung cancer | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-MY | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07589101 ↗ |
| Modality | Diagnostic / imaging agent | “This study aims to evaluate a novel 5T4 targeted nanobody PET imaging tracer, 68Ga-MY, for the detection and evaluation of solid tumors.” NCT07589101 ↗ |